Instrumental in the formation of CEPI in 2017, Erna Solberg, Norway’s Prime Minister, has long been a champion for global health security and epidemic preparedness.
Norway was one of CEPI’s founding partners when the organisation launched, in the wake of the 2014 -15 Ebola epidemic, as the result of a consensus that a coordinated, international, and intergovernmental plan was needed to develop and deploy new vaccines to prevent future epidemics.
With the Government of Norway’s announcement of a NOK2.2 billion (US$210 million) boost to CEPI’s crucial COVID-19 efforts, it has once again stepped forward as a global leader willing to do whatever it takes to neutralise the global threat posed by COVID-19
Chief Executive Officer, CEPI
Prior to the COVID-19 pandemic, Norway was one of CEPI’s biggest financial backers, providing $200 million towards the coalition’s work to develop vaccines against emerging infectious diseases like, Chikungunya, Ebola, Lassa, MERS, Nipah, and Rift Valley Fever. Then in February, 2020, Norway announced an initial NOK36 million ($4 million) to aid CEPI’s COVID-19 vaccine work. Norway’s total funding for CEPI now totals $414 million.
Subsequently, in March, 2020, CEPI estimated that $2 billion would be needed to accelerate development of a COVID-19 vaccine with 12-18 months. In response to this call the Governments of Denmark, Finland, Germany, and the United Kingdom, have pledged $443 million in support. With Norway’s substantial contribution CEPI has now raised $660 million (33%) of the $2 billion it urgently needs.
Chief Executive Officer, CEPI
The COVID-19 pandemic poses one of the greatest challenges humankind has faced in the past century. Developing vaccines is the most cost-effective way to save lives and to neutralize the grave threat posed by deadly virus. To date, CEPI has initiated eight COVID-19 vaccine projects.
The financial support CEPI has received from Norway and other governments will help it to continue its rapid progress towards producing safe and effective vaccines, which are globally accessible, within the next 12 to 18 months. However, the world must now work collectively and with urgency to address equitable access to any COVID-19 vaccine.
Image credit: World Economic Forum/ Benedikt von Loebell